Apnimed, Inc. (APMD)
| Market Cap | 999.99M |
| Revenue (ttm) | 120.15M +11,915.0% |
| Net Income | -31.83M |
| EPS | -6.28 |
| Shares Out | 40.00M |
| PE Ratio | 3.67 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,444,667 |
| Open | 22.00 |
| IPO Price | 16.00 |
| Day's Range | 16.12 - 29.15 |
| 52-Week Range | 16.00 - 27.74 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About APMD
Apnimed is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Our sole clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improvin... [Read more]
Financial Performance
In 2025, Apnimed's revenue was $38.47 million, an increase of 380.12% compared to the previous year's $8.01 million. Losses were -$128.19 million, 15.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Apnimed opens at $22.00, IPO priced at $16.00
Apnimed (APMD) priced 12M shares at $16.00. The deal size was increased to 12M shares from 10M shares of common stock and priced at the high-end of the $14.00-$16.00 range.
Apnimed 12M share IPO priced at $16.00
The deal size was increased to 12M shares of common stock from 10M shares of common stock and priced at the high-end of the $14.00-$16.00 range. BofA, Evercore ISI, Cantor…
Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO
Late-stage drug developer Apnimed is targeting a valuation of up to $608 million in its initial public offering in the United States.
Sleep apnea pill maker Apnimed files for US IPO as biotech market revives
Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering in the U.S. on Friday.
Apnimed IPO Registration Document (S-1)
Apnimed has filed to go public with an IPO on the NASDAQ